Company
Hutchmed (China) Ltd
LON:HCM
Hutchmed (China) Ltd is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,400 personnel has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved
62 stories · page 1 of 4
HUTCHMED Limited kicks off phase III cancer trial
The company’s SULANDA drug candidate will be used to treat neuroendocrine carcinoma
Hutchison China MediTech starts late-stage trial on colorectal cancer drug
Candidate fruquintinib was fast-tracked by the US authorities in June
Hutchison China MediTech starts phase II study for liver cancer treatment
HMPL-453 is a novel small molecule inhibitor targeting certain receptors that drive tumour growth
Investments and investor services
FTSE 100 closes lower but BP top gainer after Q2 results beat expectations
The FTSE 100 index closed 39.84 points lower on the day at 7,646, while the midcap FTSE 250 index plunged almost 112 points to close at 19,774
Archive
Greggs on a roll after vegan success but can it keep up the momentum?
Greggs, Reckitt Benckiser and Provident Financial are among the companies reporting results on Tuesday
Archive
Week ahead preview: Lloyds, Barclays, RBS, BT Group, BoE and US Fed
It will be a busy week for markets with a barrage of corporate earnings and interest rates decisions from the Bank of England and the US Federal Reserve.
Investments and investor services
FTSE 100 clings on to gains as rumours swirl of visit by Theresa May to the Last Chance saloon in Strasbourg
Straight from the horse's mouth? Not really. It was the deputy head of the Irish government, Simon Coveney, who confirmed that Theresa May will fly to Strasbourg this evening “to try to finalise an agreement, if that’s possible”.
Hutchison Chi-Med sheds £900mln as lung cancer trial disappoints
In a study of 527 patients in China, fruquintinib slowed the disease but failed to improve survival rates
Hutchison ChinaMediTech's colorectal cancer treatment approved in China
Colorectal cancer is the second most common cancer type in China, with about 380,000 new cases per year
Hutchison Chi-Med expects first drug launch by year end
The AIM-listed drug developer has applied for approval in China in advanced colorectal cancer
FTSE 100 closes higher, boosted by earnings and weaker pound
In London, FTSE 100 added over 38 points to finish at 7,701 - that was up on the week too, marginally - by 0.29%.